Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol) (SABER-C)

Brief Summary:
The CDC and WHO have deemed the COVID-19 virus a global pandemic of unprecedented severity in modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and has now caused upwards of 1million deaths and over 6 million infections globally. Currently, the estimated global economic impact is over 5 Trillion dollars. Understanding the host response to pathogens, specifically the cellular and humoral responses, has played an important role in new non-antibiotic therapies. Bismuth subsalicylate (Pepto-Bismol) has a potential role in the clearance and/or recurrence of enteric viral infections.
https://clinicaltrials.gov/ct2/show/NCT04811339